Loading patent…
AssigneeBoard of Regents, The University of Texas System
InventorsElizabeth M PARK, Lauren A. BYERS, Carl M. GAY, John V. HEYMACH
Estimating the term…
Aspects of the present disclosure are directed to methods for classification and treatment of small cell lung cancer (SCLC). Certain aspects pertain to treatment of a subject having SCLC using a targeting agent for a cell surface protein, where a targeting agent is selected based on a subtype classification of the SCLC. Disclosed are methods for identifying a subject as having an SCLC subtype (e.g., SCLC-A, SCLC-N, SCLC-P, SCLC-I) and administering a targeting agent configured to target a cell surface protein associated with the identified SCLC subtype. Also disclosed are compositions comprising targeting agents for treatment of SCLC.
A method for treating a subject for small cell lung cancer (SCLC), the method comprising administering a targeting agent capable of specifically binding to one or more of the proteins of Table 1, Table 2, or Table 3 to a subject determined to have SCLC-A.
A method for treating a subject for SCLC, the method comprising administering a targeting agent capable of specifically binding to one or more of the proteins of Table 4, Table 5, or Table 6 to a subject determined to have SCLC-N.
A method for treating a subject for SCLC, the method comprising administering a targeting agent capable of specifically binding to one or more of the proteins of Table 7, Table 8, or Table 9 to a subject determined to have SCLC-P.
A method for treating a subject for SCLC, the method comprising administering a targeting agent capable of specifically binding to one or more of the proteins of Table 10, Table 11, or Table 12 to a subject determined to have SCLC-I.
A method for treating a subject for SCLC, the method comprising administering a DLL3-binding protein to a subject determined to have SCLC-A.
A method for treating a subject for SCLC, the method comprising administering a CEACAM5-binding protein to a subject determined to have SCLC-A.
A method for treating a subject for SCLC, the method comprising administering a SCNN1A-binding protein to a subject determined to have SCLC-A.
A method for treating a subject for SCLC, the method comprising administering a SSTR2-binding protein to a subject determined to have SCLC-N.
A method for treating a subject for SCLC, the method comprising administering a SEMA6D-binding protein to a subject determined to have SCLC-N.
A method for treating a subject for SCLC, the method comprising administering a SGCD-binding protein to a subject determined to have SCLC-N.
A method for treating a subject for SCLC, the method comprising administering a MICA-binding protein to a subject determined to have SCLC-P.
A method for treating a subject for SCLC, the method comprising administering a TMEM87A-binding protein to a subject determined to have SCLC-P.
A method for treating a subject for SCLC, the method comprising administering a ART3-binding protein to a subject determined to have SCLC-P.
A method for treating a subject for SCLC, the method comprising administering a SLAMF8-binding protein to a subject determined to have SCLC-I.
A method for treating a subject for SCLC, the method comprising administering a MRC2-binding protein to a subject determined to have SCLC-I.
A method for treating a subject for SCLC, the method comprising administering a PIEZO1-binding protein to a subject determined to have SCLC-I.
Dependencies are inferred from the claim text.